Creative Planning
ASMB icon

Creative Planning’s Assembly Biosciences ASMB Stock Holding History

Creative Planning’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-22
Closed -$7K – 4604
2017
Q1 		$7K Buy
+22
New +$5.4K ﹤0.01% 3778
2016
Q3 		– Sell
-33
Closed -$2K – 4561
2016
Q2 		$2K Buy
+33
New +$2.17K ﹤0.01% 3977

Other funds holding ASMB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Creative Planning's ASMB Position: Q2 2017 in Review

Creative Planning sold out of Assembly Biosciences (ASMB) in Q2 2017, closing a stake of 22 shares — an estimated $7K sold.

Creative Planning first reported a position in ASMB in Q2 2016 and held it in 2 quarters. The position peaked at $7K in Q1 2017. 65 funds tracked by Wall St. Rank hold ASMB as of Q2 2017.

  • Creative Planning reported no remaining Assembly Biosciences position as of Q2 2017 after selling out during the quarter.
  • Creative Planning sold 22 Assembly Biosciences shares in Q2 2017, an estimated $7K.
  • Creative Planning first reported a position in Assembly Biosciences in Q2 2016 and held it in 2 quarters.
  • Creative Planning's Assembly Biosciences position peaked at $7K in Q1 2017.
  • 65 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2017.

Based on Creative Planning's 13F filing for Q2 2017, filed 12 Jul 2017.